Jump to content
RemedySpot.com

NEWS - 25 deaths linked to ADHD drugs

Rate this topic


Guest guest

Recommended Posts

25 deaths linked to ADHD drugs

By Bridges

ASSOCIATED PRESS

February 9, 2006

Twenty-five persons died and 54 more suffered serious cardiovascular

problems after taking drugs to treat attention-deficit (hyperactivity)

disorder between 1999 and 2003, the government says.

Children accounted for 19 of the deaths and 26 of the cases of nonfatal

cardiovascular problems, including heart attacks, strokes, hypertension,

palpitations and arrhythmia, according to a Food and Drug Administration

(FDA) report released yesterday.

The FDA report also includes data on 26 other deaths between 1999 and

2003 in ADHD-drug patients. Those include death by suicide, intentional

overdose, drowning, heatstroke and from underlying disease.

The report's release preceded an FDA panel discussion today to discuss

new ways of examining the potential cardiovascular risks of the drugs, which

include amphetamines such as Adderall, and methylphenidates, sold as

Ritalin, Concerta, Methylin and Metadate.

The few studies that have looked at longer-term use of ADHD drugs

provide little information on those risks, the FDA said.

Sales of drugs to treat ADHD have increased sharply in recent years,

with use growing at a faster rate among adults than children, according to a

recent study by Medco Health Solutions, a prescription benefit manager.

Spending on ADHD drugs soared from $759 million in 2000 to $3.1 billion in

2004, according to IMS Health, a pharmaceutical information and consulting

firm.

According to the Centers for Disease Control and Prevention (CDC) and

the Mayo Clinic, about 7.5 percent of U.S. school-age children have ADHD.

Reports estimate that the number of American children who take Ritalin,

Concerta, or similar anti-ADHD drugs at about 6 million.

Death and injury reports led the FDA's Canadian counterpart, Health

Canada, to yank the ADHD drug Adderall XR from the market for six months

last year.

A Canadian panel eventually concluded there was inadequate evidence of

increased harm from Adderall XR compared with other available therapies, a

conclusion that the FDA also reached based on data on hand.

The FDA review released yesterday found fewer than one adverse event --

that is, a death or serious injury -- per 1 million ADHD drug prescriptions

filled, with the sole exception of the 1.79 cases per million of nonfatal

cardiovascular or cerebrovascular problems reported in adults treated with

amphetamines.

Also, in some of the cases, the children who died later were found to

have had undiagnosed heart conditions. And in three of the five cases of

death in adults receiving amphetamine treatment, the patients had

pre-existing hypertension.

That suggests that hypertension " may be an important risk factor for

sudden death in the adult population, " according to the report.

The report noted, however, that the rare occurrence of sudden death in

children treated with drugs for ADHD " warrants close monitoring. " One

possibility would be to add labeling to the drugs that would recommend that

doctors consider the benefits and risks of prescribing the drugs to patients

with heart problems, the report concluded.

Adderall is made by Shire Pharmaceuticals, and Ritalin is made by

Novartis Pharmaceuticals Corp. Various other companies make generic versions

of Ritalin.

The FDA has asked its Drug Safety and Risk Management Advisory Committee

to discuss the feasibility of different ways of studying whether the deaths

are linked to use of the drugs, as well as specific ways of conducting such

studies.

That earned the FDA a rebuke from Sen. E. Grassley, Iowa

Republican, who contended that such work already should have begun.

In a letter sent Monday to acting FDA Commissioner Dr. von

Eschenbach, Mr. Grassley said in part: " I remain concerned that while both

psychiatric and cardiovascular risk signals have cropped up across this

class of drugs this past year, it appears that FDA is just now beginning to

'discuss approaches' for studying these risks. "

http://insider.washingtontimes.com/articles/normal.php?StoryID=20060209-124320-7\

473r

Not an MD

I'll tell you where to go!

Mayo Clinic in Rochester

http://www.mayoclinic.org/rochester

s Hopkins Medicine

http://www.hopkinsmedicine.org

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...